Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Hegenbart

Showing results (121-130 of 237) with videos related to

Pageof 24
Sort By:
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Blood Cancer Journal|November 7, 2018
Deferred autologous stem cell transplantation in systemic AL amyloidosisRicha Manwani, Ute Hegenbart, Shameem Mahmood, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
International Journal of Molecular Sciences|November 13, 2025
Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin AmyloidosisSelina J Hein, Fabian Aus dem Siepen, Arnt V Kristen, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Transplantation|October 24, 2014
Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantationSascha Dietrich, Aleksandar Radujkovic, Friedrich Stölzel, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 19, 2013
Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group "cutaneous lymphomas"Rose K C Moritz, Markus Ditschkowski, Claus-Detlev Klemke, et al.
European Journal of Clinical Investigation|December 16, 2020
Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosisMartin J Volz, Sven T Pleger, Andreas Weber, et al.
Pageof 24

Showing results (121-130 of 237) with videos related to

Sort By:
Pageof 24
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Blood Cancer Journal|November 7, 2018
Deferred autologous stem cell transplantation in systemic AL amyloidosisRicha Manwani, Ute Hegenbart, Shameem Mahmood, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
International Journal of Molecular Sciences|November 13, 2025
Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin AmyloidosisSelina J Hein, Fabian Aus dem Siepen, Arnt V Kristen, et al.
Haematologica|January 19, 2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmiaTobias Dittrich, Axel Benner, Christoph Kimmich, et al.
Transplantation|October 24, 2014
Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantationSascha Dietrich, Aleksandar Radujkovic, Friedrich Stölzel, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 19, 2013
Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group "cutaneous lymphomas"Rose K C Moritz, Markus Ditschkowski, Claus-Detlev Klemke, et al.
European Journal of Clinical Investigation|December 16, 2020
Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosisMartin J Volz, Sven T Pleger, Andreas Weber, et al.
Pageof 24